HDL cholesterol is not HDL--don't judge the book by its cover

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Genetics

Background:

• The traditional view linked higher high-density lipoprotein cholesterol (HDL-C) levels to reduced cardiovascular disease (CVD) risk.
• Recent genetic epidemiology studies and large clinical trials have questioned this direct association.
• This necessitates a re-evaluation of HDL's role in CVD beyond simple cholesterol levels.

Purpose of the Study:

• To challenge the established notion of HDL-cholesterol as a sole predictor of cardiovascular risk.
• To highlight the importance of exploring novel biomarkers related to HDL.
• To investigate alternative measures of HDL for more accurate cardiovascular risk assessment.

Main Methods:

• Review of genetic epidemiology findings.
• Analysis of results from large-scale, randomized clinical trials.
• Exploration of emerging biomarkers for HDL concentration, composition, and functionality.

Main Results:

• Evidence suggests that increasing HDL-cholesterol does not consistently lead to decreased cardiovascular risk.
• Genetic and clinical data indicate limitations in using HDL-C alone for risk prediction.
• Novel HDL biomarkers show promise in reflecting actual cardiovascular risk.

Conclusions:

• Cardiovascular risk reduction strategies should move beyond solely targeting HDL-cholesterol levels.
• Emerging biomarkers assessing HDL concentration, composition, and functionality are crucial for accurate risk stratification.
• Future research should focus on these advanced HDL metrics for improved CVD prevention.